Skip to main content
. 2024 Jan 4;13:1267650. doi: 10.3389/fonc.2023.1267650

Figure 2.

Figure 2

(A) Summary of tumor molecular profiling findings with therapeutic implications. *ESR1 mutation was confirmed in organoids. (B) PARIS® drug sensitivity assay workflow, including organoid generation from core biopsy, characterization, and report generation. Figure generated using Biorender. (C) Brightfield photomicrograph of the patient’s cultured tumor organoids. Scale bar = 10 µm. (D) Table of top-scoring drugs in green from the PARIS® assay.